首页> 外文OA文献 >Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

【2h】

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

机译：在晚期实体瘤患者中以间歇和连续给药方案给药时，口服细胞周期蛋白依赖性激酶抑制剂AZD5438的安全性，耐受性，药代动力学和药效学

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: AZD5438 is an orally bioavailable inhibitor of cyclin E-cdk2, cyclin A-cdk2 and cyclin B-cdk1 complexes. Three phase I studies assessed the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5438 when administered in different dosing schedules.

机译：背景：AZD5438是细胞周期蛋白E-cdk2，细胞周期蛋白A-cdk2和细胞周期蛋白B-cdk1复合物的口服生物利用抑制剂。当以不同的给药方案给药时，三期I期研究评估了AZD5438的临床安全性，耐受性，药代动力学和药效学。

著录项

作者
Boss, D. S.; Schwartz, G. K.; Middleton, M. R.; Amakye, D. D.; Swaisland, H.; Midgley, R. S.; Ranson, M.; Danson, S.; Calvert, H.; Plummer, R.; Morris, C.; Carvajal, R. D.; Chirieac, L. R.; Schellens, J. H. M.; Shapiro, G. I.;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. [J] . Boss DS, Schwartz GK, Middleton MR, Annals of oncology: official journal of the European Society for Medical Oncology . 2010,第4期

机译：在晚期实体瘤患者中以间歇和连续给药方案给药时，口服细胞周期蛋白依赖性激酶抑制剂AZD5438的安全性，耐受性，药代动力学和药效学。
2. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administeredn at intermittent and continuous dosing schedules in patients with advanced solid tumours [J] . G. I. Shapiro Annals of Oncology . 2010,第4期

机译：晚期实体瘤患者以间歇和连续给药方案给药时，口服细胞周期蛋白依赖性激酶抑制剂AZD5438的安全性，耐受性，药代动力学和药效学
3. A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies [J] . Das Millie, Padda Sukhmani K., Frymoyer Adam, Cancer chemotherapy and pharmacology. . 2018,第3期

机译：具有晚期固体恶性肿瘤患者的间歇和连续给药调度，对多元小分子酪氨酸激酶抑制剂XL647的一种安全性，耐受性和药代动力学分析
4. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
5. Safety tolerability pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours [O] . D. S. Boss, G. K. Schwartz, M. R. Middleton, -1

机译：在晚期实体瘤患者中以间歇和连续给药方案给药时口服细胞周期蛋白依赖性激酶抑制剂AZD5438的安全性耐受性药代动力学和药效学
6. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours [O] . Christophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, 2020

机译：1期剂量升级研究，以评估ASIDNA的安全性，药代动力学和药效学，一流的DNA修复抑制剂，静脉注射治疗晚期实体肿瘤的患者

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅